In this retrospective multicenter cohort study involving 387 patients, median (range) age 63 (17-88) years and 235 (60.7%) were male, with stage III to IV melanomas, researchers determined the incidence, time course, spectrum, and associations of chronic immune-related adverse events (irAEs) arising from adjuvant anti-programmed cell death 1 (anti–PD-1) therapy.
Publications
NCDB Analysis of Melanoma 2004-2015: Epidemiology and Outcomes by Subtype, Sociodemographic Factors Impacting Clinical Presentation, and Real-World Survival Benefit of Immunotherapy Approval
The incidence of invasive melanoma is rising, and approval for the first immune checkpoint inhibitor (ICI) to treat metastatic melanoma occurred in 2011.
High Risk Melanoma Patients Can Benefit from Routine Screening and Education
Patients at high risk of melanoma who undergo routine skin cancer screening and education are more likely to be diagnosed with earlier stage melanomas, according to a study published in Cancer Epidemiology, Biomarkers & Prevention
FDA Grants Orphan Drug Designation to Cavrotolimod for Merkel Cell Carcinoma
The FDA has granted an orphan drug designation to cavrotolimod (AST-008) for the treatment of patients with Merkel cell carcinoma (MCC), according to an announcement from Exicure, Inc.1